Anixa Biosciences wins Australian patent for breast cancer vaccine

Anixa Biosciences Inc. has secured its first Australian patent for its breast cancer vaccine technology, extending exclusivity in Australia until 2040. The patent covers vaccine adjuvants and formulations licensed from Cleveland Clinic. Phase 1 data indicated the vaccine was safe, well-tolerated, and elicited immune responses in over 74% of participants.